Literature DB >> 29091763

Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.

Masayuki Nakamori1, Kohei Hamanaka2, James D Thomas3, Eric T Wang3, Yukiko K Hayashi4, Masanori P Takahashi5, Maurice S Swanson3, Ichizo Nishino2, Hideki Mochizuki6.   

Abstract

Myotonic dystrophy types 1 (DM1) and 2 (DM2) are dominantly inherited neuromuscular disorders caused by a toxic gain of function of expanded CUG and CCUG repeats, respectively. Although both disorders are clinically similar, congenital myotonic dystrophy (CDM), a severe DM form, is found only in DM1. CDM is also characterized by muscle fiber immaturity not observed in adult DM, suggesting specific pathological mechanisms. Here, we revealed upregulation of the interleukin-6 (IL-6) myokine signaling pathway in CDM muscles. We also found a correlation between muscle immaturity and not only IL-6 expression but also expanded CTG repeat length and CpG methylation status upstream of the repeats. Aberrant CpG methylation was associated with transcriptional dysregulation at the repeat locus, increasing the toxic RNA burden that upregulates IL-6. Because the IL-6 pathway is involved in myocyte maturation and muscle atrophy, our results indicate that enhanced RNA toxicity contributes to severe CDM phenotypes through aberrant IL-6 signaling.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTCF; ER stress; IL-6; NF-κB; cytokine; muscular dystrophy; splicing; trinucleotide

Mesh:

Substances:

Year:  2017        PMID: 29091763      PMCID: PMC5689469          DOI: 10.1016/j.celrep.2017.10.018

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  60 in total

Review 1.  Control of NF-κB and inflammation by the unfolded protein response.

Authors:  Masanori Kitamura
Journal:  Int Rev Immunol       Date:  2011-02       Impact factor: 5.311

2.  CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus.

Authors:  G N Filippova; C P Thienes; B H Penn; D H Cho; Y J Hu; J M Moore; T R Klesert; V V Lobanenkov; S J Tapscott
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

3.  Alternative splicing dysregulation secondary to skeletal muscle regeneration.

Authors:  James P Orengo; Amanda J Ward; Thomas A Cooper
Journal:  Ann Neurol       Date:  2011-03-11       Impact factor: 10.422

4.  Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Jihae Shin; Yuan Yuan; Stuart G Beattie; Thurman M Wheeler; Charles A Thornton; Maurice S Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

5.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart.

Authors:  Auinash Kalsotra; Xinshu Xiao; Amanda J Ward; John C Castle; Jason M Johnson; Christopher B Burge; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

6.  Somatic instability of CTG repeat in myotonic dystrophy.

Authors:  T Ashizawa; J R Dubel; Y Harati
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

7.  Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2.

Authors:  Rosanna Cardani; Simona Baldassa; Annalisa Botta; Fabrizio Rinaldi; Giuseppe Novelli; Enzo Mancinelli; Giovanni Meola
Journal:  Neuromuscul Disord       Date:  2009-04-03       Impact factor: 4.296

8.  Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.

Authors:  T Tsujinaka; J Fujita; C Ebisui; M Yano; E Kominami; K Suzuki; K Tanaka; A Katsume; Y Ohsugi; H Shiozaki; M Monden
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy.

Authors:  Lise Barbé; Stella Lanni; Arturo López-Castel; Silvie Franck; Claudia Spits; Kathelijn Keymolen; Sara Seneca; Stephanie Tomé; Ioana Miron; Julie Letourneau; Minggao Liang; Sanaa Choufani; Rosanna Weksberg; Michael D Wilson; Zdenek Sedlacek; Cynthia Gagnon; Zuzana Musova; David Chitayat; Patrick Shannon; Jean Mathieu; Karen Sermon; Christopher E Pearson
Journal:  Am J Hum Genet       Date:  2017-03-02       Impact factor: 11.025

10.  Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice.

Authors:  Laura Pelosi; Maria Grazia Berardinelli; Laura Forcina; Elisa Spelta; Emanuele Rizzuto; Carmine Nicoletti; Carlotta Camilli; Erika Testa; Angela Catizone; Fabrizio De Benedetti; Antonio Musarò
Journal:  Hum Mol Genet       Date:  2015-08-06       Impact factor: 6.150

View more
  17 in total

1.  Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1.

Authors:  Masayuki Nakamori; Hiroshi Shimizu; Kotaro Ogawa; Yuhei Hasuike; Takashi Nakajima; Hidetoshi Sakurai; Toshiyuki Araki; Yukinori Okada; Akiyoshi Kakita; Hideki Mochizuki
Journal:  Brain Commun       Date:  2022-06-10

2.  A comprehensive atlas of fetal splicing patterns in the brain of adult myotonic dystrophy type 1 patients.

Authors:  Max J F Degener; Remco T P van Cruchten; Brittney A Otero; Eric T Wang; Derick G Wansink; Peter A C 't Hoen
Journal:  NAR Genom Bioinform       Date:  2022-03-08

Review 3.  Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy.

Authors:  Sandra O Braz; Julien Acquaire; Geneviève Gourdon; Mário Gomes-Pereira
Journal:  Front Neurol       Date:  2018-07-10       Impact factor: 4.003

4.  Alternative splicing of clathrin heavy chain contributes to the switch from coated pits to plaques.

Authors:  Gilles Moulay; Jeanne Lainé; Mégane Lemaître; Masayuki Nakamori; Ichizo Nishino; Ghislaine Caillol; Kamel Mamchaoui; Laura Julien; Florent Dingli; Damarys Loew; Marc Bitoun; Christophe Leterrier; Denis Furling; Stéphane Vassilopoulos
Journal:  J Cell Biol       Date:  2020-09-07       Impact factor: 10.539

5.  Recovery in the Myogenic Program of Congenital Myotonic Dystrophy Myoblasts after Excision of the Expanded (CTG)n Repeat.

Authors:  Laurène M André; Remco T P van Cruchten; Marieke Willemse; Karel Bezstarosti; Jeroen A A Demmers; Ellen L van Agtmaal; Derick G Wansink; Bé Wieringa
Journal:  Int J Mol Sci       Date:  2019-11-13       Impact factor: 5.923

6.  The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1.

Authors:  Ranjan Batra; David A Nelles; Daniela M Roth; Florian Krach; Curtis A Nutter; Takahiro Tadokoro; James D Thomas; Łukasz J Sznajder; Steven M Blue; Haydee L Gutierrez; Patrick Liu; Stefan Aigner; Oleksandr Platoshyn; Atsushi Miyanohara; Martin Marsala; Maurice S Swanson; Gene W Yeo
Journal:  Nat Biomed Eng       Date:  2020-09-14       Impact factor: 25.671

Review 7.  Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy.

Authors:  Laurène M André; C Rosanne M Ausems; Derick G Wansink; Bé Wieringa
Journal:  Front Neurol       Date:  2018-05-28       Impact factor: 4.003

Review 8.  Role of Myokines in Myositis Pathogenesis and Their Potential to be New Therapeutic Targets in Idiopathic Inflammatory Myopathies.

Authors:  Vlad Mageriu; Emilia Manole; Alexandra E Bastian; Florica Staniceanu
Journal:  J Immunol Res       Date:  2020-07-24       Impact factor: 4.818

9.  Activation of the interferon type I response rather than autophagy contributes to myogenesis inhibition in congenital DM1 myoblasts.

Authors:  Milena Rizzo; Pascale Beffy; Renata Del Carratore; Alessandra Falleni; Virginia Pretini; Romina D'Aurizio; Annalisa Botta; Monica Evangelista; Andrea Stoccoro; Fabio Coppedè; Denis Furling; Marcella Simili
Journal:  Cell Death Dis       Date:  2018-10-19       Impact factor: 8.469

Review 10.  STAT3 in Skeletal Muscle Function and Disorders.

Authors:  Eleonora Guadagnin; Davi Mázala; Yi-Wen Chen
Journal:  Int J Mol Sci       Date:  2018-08-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.